Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
This is a phase II, open-label clinical study prospectively enrolling 40 metastatic patients with non small cell lung cancer. The study will enroll patients at King Abdulaziz Medical City, Riyadh.

Sub-sites will be open for patient accrual in selected centers in the Kingdom.
Non-small Cell Lung Cancer Metastatic
DRUG: cisplatin, docetaxel
Efficacy, Efficacy will be measured by calculating the following:

* Response rate using Response Evaluation Criteria for Solid Tumor criteria
* Time to Disease progression or Death
* Overall Survival, 3 years
Progression free survival, safety, * To determine progression free survival, median survival and 1 year survival of the studied population.
* To evaluate the Number of participants with Adverse Events and Serious Adverse Events.Safety will include 4 parameters to be collected for all patients who receive the study regimen which are:

  * Adverse Events
  * Laboratory Assessments
  * Vital Signs
  * Physical Examinations, 3 years
The cisplatin/docetaxel is established standard in the first line management of metastatic non small cell lung cancer in the United States, Europe and Asia. However, the safety and efficacy of this regimen was not studied systematically in Middle Eastern population. The aim of this study is to study the efficacy and safety of this regimen in our patient population